2019 American Transplant Congress
Performance Improvement Initiative: Ambulatory Tool to Improve Tacrolimus Intrapatient Variability (IPV) Monitoring in Kidney & Liver Transplant Recipients
1University of Cincinnati, Cincinnati, OH, 2UC Health, Cincinnati, OH
*Purpose: High tacrolimus (TAC) intrapatient variability (IPV) is associated with poorer outcomes. Manual monitoring of TAC IPV is labor intensive and not always feasible. As…2019 American Transplant Congress
The Reduced Tacrolimus Metabolism Rate and Its Association with Estimated Glomerular Filtration Rate and Interstitial Fibrosis: A Study Using Korean Organ Transplantation Registry (KOTRY) Dataset
*Purpose: Tacrolimus is the key drug in clinical transplant, which has narrow therapeutic index. A few studies reported the association of tacrolimus metabolism rate with…2019 American Transplant Congress
Identification of Adult Liver Transplant Recipients Eligible to Participate in an Immunosuppression Withdrawal Trial Employing Non-Invasive Assessments of Allograft Status
*Purpose: Liver Immunosuppression Free Trial (LIFT) is a multicentre international prospective randomised controlled trial of biomarker-guided immunosuppression withdrawal in adult liver transplant recipients who meet…2019 American Transplant Congress
Impact of Steroid-Free Protocol on Incidence of Posttransplantation Diabetes Mellitus: A Prospective, Randomized, Multicenter, Open-Label, Controlled Trial in Renal Transplant Recipients
*Purpose: Comparison of two immunosuppressive protocols, steroid-free with antithymocyte globulin (ATG) induction, and steroid containing with basiliximab induction, regarding the incidence of PTDM, one year…2019 American Transplant Congress
Impact of Belatacept Conversion on Renal Function, Histology and Gene Expression in Kidney Transplant Patients with Interstitial Fibrosis and Tubular Atrophy
*Purpose: Prior studies on the conversion of tacrolimus (Calcineurin Inhibitor; CNI) to belatacept have been limited in scope due to either the absence of, post-conversion…2019 American Transplant Congress
A Randomized Controlled Clinical Trial of Thymoglobulin® and Extended Delay of Calcineurin Inhibitor Therapy for Renal Protection after Liver Transplantation: A Multicenter Study
*Purpose: Thymoglobulin® (r-ATG) has been used as induction therapy in liver transplantation (LT). No prospective, randomized, controlled, trial (RCT) has been performed to evaluate effect…2019 American Transplant Congress
The Impact of Calcineurin Inhibitors on De Novo DSA in Primary Kidney Transplantation
Nagoya Daini Red Cross Hospital, Nagoya Aichi, Japan
*Purpose: De novo DSA was demonstrated as a cause of chronic AMR, leading to worse graft survival. New strategies to treat chronic AMR have been…2019 American Transplant Congress
Everolimus/Low Tacrolimus Exposure versus Sodium Mycophenolate/Standard Tacrolimus for the Elderly Kidney Transplant Recipient. A 4-y Follow-Up of the nEverOld Trial
*Purpose: The standard immunosuppressive regimen used for younger patients may not be adequate for the elderly cohort.*Methods: The nEverOld is a prospective, single-center, randomized trial…2019 American Transplant Congress
Early Rejection Outcomes with IL-2 vs. ATG Induction among Kidney Transplant Recipients Induction Differences with Early Steroid Withdrawal
University Hospitals Cleveland Medical Center, Cleveland, OH
*Purpose: Early steroid withdrawal in kidney transplant (Ktx) patients is controversial and has demonstrated an increased risk of acute rejection with similar long-term outcomes. Data…2019 American Transplant Congress
Alemtuzumab versus Antithymocyte Globulin Induction Immunosuppression in Highly Sensitized Kidney Transplant Recipients
1Tampa General Hospital, Tampa, FL, 2Florida Kidney Physicians, Tampa, FL
*Purpose: Lymphocyte depleting agents such as rabbit anti-thymocyte globulin (rATG) and alemtuzumab are used for induction in highly sensitized (PRA ≥30%) kidney transplant recipients (KTRs).…
- « Previous Page
- 1
- …
- 53
- 54
- 55
- 56
- 57
- …
- 138
- Next Page »